1cP-AL-LAD

Uncontrolled hypertension, Heart failure, Recent myocardial infarction, Severe arrhythmias

LSD at 100–200 µg in controlled human studies produces moderate, self-limiting cardiovascular effects including increased heart rate and blood pressure (Holze 2022, Ley 2023). These effects are expected for 1cP-AL-LAD via its presumed active metabolite AL-LAD but have not been measured directly. Individuals with serious cardiovascular conditions face elevated risk from sympathomimetic stimulation.

Personal history of HPPD, Family history of HPPD

Hallucinogen persisting perception disorder (HPPD) is a documented rare adverse outcome of 5-HT₂A agonist use, attributed to imbalance of inhibitory-excitatory activity in visual processing circuits (Litjens et al. 2014). Re-exposure to serotonergic psychedelics may trigger recurrence or exacerbation. Most documented cases involve LSD; no HPPD cases have been reported for 1cP-AL-LAD specifically.

Schizophrenia spectrum disorders, Bipolar disorder with psychotic features, Family history of psychotic disorders

Personal or family history of psychotic disorders is an absolute contraindication for all serotonergic psychedelics. 5-HT₂A agonism disrupts thalamocortical gating and can precipitate acute psychotic episodes in predisposed individuals. This contraindication is class-level — no substance-specific data exist for 1cP-AL-LAD.

Active major depressive episode with suicidal ideation, Acute anxiety disorders, PTSD in acute crisis, Personality disorders with emotional dysregulation

Unstable psychiatric conditions increase vulnerability to adverse psychological outcomes during psychedelic experiences. Emotional enhancement, ego dissolution, and thought loops can exacerbate existing distress. Simonsson et al. (2023) identified negative mindset as a key modifiable risk factor for challenging experiences. This is a class-level relative contraindication.

Pregnancy, Breastfeeding

No reproductive safety data exist for 1cP-AL-LAD or AL-LAD. The serotonergic psychedelic class has not been systematically studied in pregnancy or breastfeeding. Given the absence of any safety data and the potential for serotonergic effects on fetal development, use during pregnancy or breastfeeding is contraindicated.

Current lithium therapy

Concurrent lithium use was identified as the top medication risk factor for severe adverse psychedelic outcomes in a nationally representative epidemiological survey (Simonsson et al. 2023, N=613). The combination carries seizure risk and produces dangerously amplified effects. This is a class-level contraindication applicable to all serotonergic psychedelics including 1cP-AL-LAD.

Current MAOI medication use

Concurrent use of monoamine oxidase inhibitors with serotonergic psychedelics creates a mechanistically plausible risk of serotonin toxicity. MAO inhibition prevents serotonin breakdown while the psychedelic directly stimulates serotonin receptors, potentially producing serotonin syndrome (altered mental status, autonomic instability, neuromuscular hyperactivity). This is a class-level contraindication — no 1cP-AL-LAD-specific interaction data exist.

Current SSRI use, Current SNRI use, Current tramadol use

Concurrent serotonergic medications interact with 1cP-AL-LAD via two mechanisms: SSRIs and SNRIs may attenuate psychedelic effects through 5-HT₂A receptor competition/downregulation, leading to unpredictable dosing. Tramadol inhibits the serotonin transporter (Baldo 2018) and creates a mechanistically plausible serotonin toxicity risk when combined with a 5-HT₂A agonist. The tramadol combination is classified as dangerous in seed data.